The Muscle Loss Problem with GLP-1s — and How to Prevent It
Dr. RP, MD — Board-Certified, Emergency Medicine & Critical Care Medicine — Founder, Analog Precision Medicine
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and the dual GLP-1/GIP agonist tirzepatide (Mounjaro, Zepbound) have transformed obesity management. The cardiovascular and metabolic benefits are real and well-documented. Less well-publicized is what these drugs do to skeletal muscle. This article reviews the evidence on lean mass loss with GLP-1 therapy, identifies who is most at risk, and outlines the prevention strategy supported by current data.
Quick Take
Approximately 25–40% of weight lost on standard-dose semaglutide or tirzepatide is lean body mass — including muscle.
Lean mass loss is greater in older adults, postmenopausal women, sedentary patients, and those rapidly titrated to maximum dose.
Resistance training and high-protein intake (1.2–1.6 g/kg/day; 1.6–2.0 g/kg/day in adults over 65) are the most evidence-supported preventive strategies.
Slower titration, periodic DEXA monitoring, and individualized dose targeting reduce excess lean mass loss.
Investigational combinations (bimagrumab + semaglutide, pemvidutide) significantly improve body composition outcomes; phase 3 data are pending.
Why Muscle Matters
Skeletal muscle is more than locomotion. It is the body's largest reservoir of glucose disposal, a major endocrine organ, and a primary determinant of metabolic rate, frailty risk, and long-term mortality. Sarcopenia — age-related loss of muscle mass and strength — independently predicts falls, fractures, hospitalization, and death. Sarcopenic obesity, the combination of low muscle mass with elevated body fat, carries even greater risk than either condition alone. Any weight loss strategy that disproportionately depletes lean mass therefore deserves careful evaluation, regardless of the visible benefits.
What the Trials Show
Semaglutide (STEP-1)
The STEP-1 trial randomized 1,961 adults to once-weekly semaglutide 2.4 mg or placebo for 68 weeks. In the body composition substudy (140 participants with paired DEXA scans), semaglutide-treated participants lost 15.0% of body weight, with a 6.92 kg (−9.7%) reduction in total lean body mass. Lean mass accounted for approximately 39–45% of total weight lost. Notably, the proportion of lean mass relative to total body mass increased by 3.0 percentage points because fat mass loss exceeded lean mass loss.
Tirzepatide (SURMOUNT-1)
The SURMOUNT-1 trial demonstrated up to 22.5% body weight reduction at 72 weeks with tirzepatide 15 mg. In the DEXA substudy of 160 participants, tirzepatide produced a 21.3% reduction in body weight, 33.9% reduction in fat mass, and 10.9% reduction in lean mass. Approximately 25% of weight lost was lean mass — proportionally less than semaglutide, though still substantial in absolute terms.
Network Meta-Analysis
A 2025 systematic review and network meta-analysis of 22 randomized trials (2,258 participants) found that GLP-1 receptor agonists at standard weight-management doses produce roughly 25% of total weight loss as lean mass, with high-dose tirzepatide and semaglutide among the least effective at preserving lean mass. Liraglutide at lower doses was the only molecule in the class to achieve significant weight reduction without significant lean mass loss.
Real-World Data (2026)
A large EHR-linked digital phenotyping study published in early 2026 analyzed body composition outcomes in 7,965 first-episode GLP-1 users (semaglutide n=6,196; tirzepatide n=1,769) with paired measurements in routine care:
Tirzepatide produced greater relative lean body mass loss than semaglutide at 3, 6, 9, and 12 months — a reversal of the more favorable signal in the registration trials.
A "Depletive GLP-1 metabotype" (>20% total body weight loss with >5% lean mass loss) occurred in 10.3% of tirzepatide users versus 6.7% of semaglutide users in the first year.
Baseline musculoskeletal pain was the strongest predictor of greater lean mass loss, suggesting reduced exercise capacity drives the disparity.
Adaptive vs. Maladaptive: An Important Nuance
A 2024 Circulation primer reviewed whether GLP-1-related lean mass loss is clinically meaningful or merely proportional. Drawing on MRI-based muscle volume data, the authors concluded that on average, observed lean mass changes are adaptive — within the range expected for the magnitude of fat loss achieved.
The SEMALEAN study (2025), a prospective French trial of 106 patients on semaglutide 2.4 mg, supported this view: handgrip strength improved by 4.5 kg at 12 months, and the prevalence of sarcopenic obesity dropped from 49% to 33%.
These findings suggest that for the average patient with severe obesity, GLP-1 therapy improves muscle function despite reducing muscle quantity. However, averages obscure individual variability — and the patients most likely to suffer adverse outcomes are typically underrepresented in registration trials.
Who Is Most at Risk
Adults over 65. Post-hoc analyses of the STEP trials show greater proportional lean mass loss and slower functional recovery in older participants. Anabolic resistance reduces the muscle-protein-synthesis response to a given protein dose with age.
Postmenopausal women. Estrogen decline reduces baseline muscle protein synthesis, amplifying the catabolic effect of caloric deficit.
Sedentary patients or those with mobility limitations. Baseline musculoskeletal pain was the strongest single predictor of excess lean mass loss in the 2026 real-world analysis.
Highly active or athletic patients. While not at risk for clinical sarcopenia, performance-oriented patients can experience meaningful declines in strength and power output without proactive countermeasures.
Patients titrated rapidly to maximum dose. Without a concurrent body composition strategy, rapid titration accelerates lean mass depletion.
Evidence-Based Prevention Strategy
1. Protein Intake
Consensus guidance across recent reviews and clinical perspectives:
For a 90 kg adult, this translates to approximately 110–145 g of protein daily — substantially above the typical baseline intake. Appetite suppression makes this target difficult to achieve through whole foods alone; protein supplementation (whey, casein, or high-quality plant-based blends) is often necessary.
2. Resistance Training
Resistance training is the only intervention demonstrated to send a sufficient signal to skeletal muscle to maintain mass during a calorie deficit. Cardiovascular exercise, while beneficial for other endpoints, does not preserve muscle. Minimum effective dose:
2–3 sessions per week
Compound movements (squat, hinge, press, pull, carry)
2–3 sets of 8–12 repetitions per exercise
Progressive overload over time
3. Slow, Targeted Titration
Faster weight loss correlates with greater proportional lean mass loss. Titration to maximum dose is not always indicated. If target weight loss is achieved at a sub-maximum dose, escalation is unlikely to provide additional clinical benefit and may worsen body composition outcomes.
4. Body Composition Monitoring
Serial DEXA scanning at baseline and at 6 and 12 months allows direct measurement of lean and fat mass changes. The scale alone cannot distinguish between favorable and unfavorable body composition trajectories at the same total weight loss.
Investigational Approaches
Bimagrumab + Semaglutide (BELIEVE)
Bimagrumab is a first-in-class monoclonal antibody targeting activin type II receptors, which inhibits myostatin signaling and promotes muscle preservation. The Phase 2b BELIEVE trial (n=507) first results were presented at ADA 2025 and published in Nature Medicine in early 2026:
Pemvidutide (MOMENTUM)
A GLP-1/glucagon dual receptor agonist. The Phase 2 MOMENTUM trial showed 10.3% body weight loss at 48 weeks with only ~22% of weight loss from lean mass — approximately half the lean mass loss seen with semaglutide at comparable weight reduction. The glucagon receptor activation appears to direct catabolism preferentially toward fat oxidation while sparing muscle protein.
The AnalogPM Approach
For patients considering or currently on GLP-1 therapy, a precision-medicine evaluation should include:
Baseline DEXA body composition with regional analysis
Comprehensive metabolic and lipid panel including ApoB, fasting insulin, HbA1c, hsCRP, IGF-1, vitamin D, and (where indicated) testosterone
Detailed exercise and dietary history with quantified protein intake
Individualized titration plan with explicit dose-response targeting
Resistance training prescription tailored to musculoskeletal status
Protein intake target with practical execution strategy
Repeat DEXA at 6 and 12 months
Periodic functional assessment (handgrip strength, gait speed where indicated)
“The objective is not maximum weight loss. The objective is optimal body composition change with preserved or improved physical function — an outcome that requires deliberate strategy, not the default protocol.”
Dr. RP, MD is dual board-certified in Emergency Medicine and Critical Care Medicine and is the founder of Analog Precision Medicine, a precision medicine practice in Southern California. This article is for educational purposes only and does not constitute medical advice or establish a physician-patient relationship.
← Back to Blog